Supplementary Figure 1.

A. 4T1, MDA-MB-231, and BT-549 cell lines were infected with 1 MOI of VSVd51 and incubated for 4, 24, 48, or 72 hours. Western blot analysis was performed using antibodies against PARP-1, cleaved PARP-1, Caspase-3, cleaved Caspase-3, and β-Actin.

B. The percentage of apoptosis was determined by flow cytometry. The data are presented as mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001 compared to the control group.

C. Western blot analysis was performed using antibodies against LC3-I, LC3-II, and β-Actin.

D. 4T1 and MDA-MB-231 cells were treated with doxorubicin (Doxo) or VSVd51 and incubated for 4, 24, or 48 hours. Western blot analysis was performed using antibodies against HMGB1.

E. MDA-MB-231 cells were treated with doxorubicin (Doxo) or VSVd51 and incubated for 4, 24, or 48 hours. Western blot analysis was performed using antibodies against HMGB1.